What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function,can be managed by dose reduction and temporary of QL1074 to interruption.”In the company’s words, NCT06406205 on ClinicalTrials.gov
- Tested for
- Lupus Nephritis
- Main trialPhase 3
- “The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.”In the company’s words, NCT06406205 on ClinicalTrials.gov
Other drugs for Lupus Nephritis
- AnifrolumabAstraZeneca · Phase 3
- IanalumabNovartis Pharmaceuticals · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- CenerimodViatris Innovation GmbH · Phase 3
- HLX79Henlius · Phase 2
Coming up1
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026